Novel nano-membrane technology to enable development of therapeutic antibodies targeting membrane proteins

Reference number 2018-04264
Coordinator Salipro Biotech AB
Funding from Vinnova SEK 500 000
Project duration November 2018 - July 2019
Status Ongoing
Venture Banbrytande idéer inom industriell utveckling
Call Banbrytande idéer inom industriell utveckling 2018

Purpose and goal

The aim of the project is to determine the potential of the Salipro® technology in the context of development of therapeutic antibodies via phage display

Expected results and effects

The project aims at generating membrane protein specific antibodies using the proprietary Salipro® technology. The results will pave an entirely novel way to generate drug target specific antibodies in an industry setting.

Planned approach and implementation

This project is a collaboration between Salipro Biotech AB and the Drug Discovery & Development (DDD) Platform at Science for Life Laboratory (SciLifeLabs). Salipro Biotech AB reconstitutes membrane protein drug targets into the Salipro® nano-membrane particles and SciLifeLabs selects and characterizes drug target specific antibodies.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.